The U.S. Food and Drug Administration (FDA) has approved a new injectable form of a medicine called valproate sodium. This medicine is used to treat certain types of seizures. The injectable version is for short-term use when a person cannot take the medicine by mouth. This might happen during recovery from surgery or if someone has a stomach issue that prevents swallowing pills. It helps ensure that seizure treatment is not interrupted.
This approval means there is now a generic, intravenous (IV) option available. It is not a new type of medicine, but a new way to deliver an existing one. The goal is to provide continuity of care for patients who temporarily need an alternative to pills. Doctors can use this injection to maintain therapy until the patient is able to switch back to taking the medicine orally.
It is important to know that this injection is approved for short-term use, generally not more than 14 days. The long-term safety of using the injection for extended periods has not been studied. The drug's label states that patients should be switched back to an oral form as soon as it is medically possible.
As with any new medical option, this approval is a regulatory step that makes this form of the drug available. It does not change an individual's treatment plan. Patients and caregivers with questions about this or any medication should have a conversation with their doctor to understand what is right for their specific situation.